Open Collections

UBC Faculty Research and Publications

Diversity of Canadian meningococcal serogroup B isolates and estimated coverage of an investigational meningococcal serogroup B vaccine (4CMenB) Bettinger, Julie A.; Scheifele, David W.; Halperin, Scott A.; Vaudry, Wendy; Findlow, Jamie; Borrow, Ray; Medini, Duccio; Tsang, Raymond

Abstract

Background: In collaboration with the Canadian Immunization Monitoring Program Active (IMPACT), the National Microbiology Laboratory,the UK Health Protection Agency and Novartis Vaccines, we tested the potential of an investigational 4-component meningococcal B vaccine (4CMenB) to cover Canadian strains circulating from 2006 to 2009. Methods: IMPACT meningococcal surveillance is population based and includes over 50% of Canadian adults and children. All isolates were characterized by Meningococcal Antigen Typing System (MATS) and sequencing for factor H-binding protein (fHbp), Neisseria Heparin Binding Antigen (NHBA) and Neisserial adhesin A(NadA). Results: In total, 157 isolates were tested. Overall, 4CMenB MATS predicted strain coverage was 66% (95% CI: 46–78%), with 26%, 29% and 11% of strains covered by one,two and three vaccine antigens, respectively. The coverage of each antigen was as follows: 13% PorA, 1% NadA, 52% fHbp and 51% NHBA.The majority of strains for clonal complex (cc) 1/44 and cc 60 were covered by NHBA; the majority of strains for cc269 and cc32 were covered by fHbp and NHBA. Coverage for two prevalent strains (sequence type (ST)-269 and ST-154)was 95% and 100%, respectively. Conclusions: 4CMenB has the potential to protect against a significant proportion of Canadian invasive MenB strains.

Item Metadata

Title
Diversity of Canadian meningococcal serogroup B isolates and estimated coverage of an investigational meningococcal serogroup B vaccine (4CMenB)
Creator
Bettinger, Julie A.; Scheifele, David W.; Halperin, Scott A.; Vaudry, Wendy; Findlow, Jamie; Borrow, Ray; Medini, Duccio; Tsang, Raymond
Date Issued
2014
Description
Background: In collaboration with the Canadian Immunization Monitoring Program Active (IMPACT), the National Microbiology Laboratory,the UK Health Protection Agency and Novartis Vaccines, we tested the potential of an investigational 4-component meningococcal B vaccine (4CMenB) to cover Canadian strains circulating from 2006 to 2009. Methods: IMPACT meningococcal surveillance is population based and includes over 50% of Canadian adults and children. All isolates were characterized by Meningococcal Antigen Typing System (MATS) and sequencing for factor H-binding protein (fHbp), Neisseria Heparin Binding Antigen (NHBA) and Neisserial adhesin A(NadA). Results: In total, 157 isolates were tested. Overall, 4CMenB MATS predicted strain coverage was 66% (95% CI: 46–78%), with 26%, 29% and 11% of strains covered by one,two and three vaccine antigens, respectively. The coverage of each antigen was as follows: 13% PorA, 1% NadA, 52% fHbp and 51% NHBA.The majority of strains for clonal complex (cc) 1/44 and cc 60 were covered by NHBA; the majority of strains for cc269 and cc32 were covered by fHbp and NHBA. Coverage for two prevalent strains (sequence type (ST)-269 and ST-154)was 95% and 100%, respectively. Conclusions: 4CMenB has the potential to protect against a significant proportion of Canadian invasive MenB strains.
Subject
Serogroup B vaccines; 4CMenB coverage; Meningococcal Antigen Typing System; Invasive meningococcal disease; Meningitis
Genre
Article
Type
Text
Language
eng
Date Available
2016-03-10
Provider
Vancouver : University of British Columbia Library
Rights
Attribution-NonCommercial-NoDerivs 2.5 Canada
DOI
10.14288/1.0228098
URI
http://hdl.handle.net/2429/57123
Affiliation
Medicine, Department of; Medicine, Faculty of; Pediatrics, Department of; Non UBC
Citation
Bettinger, J. A., Scheifele, D. W., Halperin, S. A., Vaudry, W., Findlow, J., Borrow, R., . . . Tsang, R. (2013). Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB). Vaccine, 32(1), 124-130.
Publisher DOI
10.1016/j.vaccine.2013.03.063
Peer Review Status
Reviewed
Scholarly Level
Faculty
Rights URI
http://creativecommons.org/licenses/by-nc-nd/2.5/ca/
Aggregated Source Repository
DSpace

Item Media

Item Citations and Data

Rights

Attribution-NonCommercial-NoDerivs 2.5 Canada